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ABSTRACT 
 
Madan, Ashish. M.S.M.E., Department of Mechanical and Materials Engineering, Wright 
State University, 2018. In vitro assessment of the effects of valvular stenosis on aorta 
hemodynamics and left ventricular function. 
 
Calcific aortic stenosis (CAS) is the most common valvular heart disease and is associated 
with aortopathy and ventricular dysfunction. Hemodynamic alterations due CAS could 
affect the aorta lining (endothelium), that is in direct contact with the blood, triggering 
adverse biological responses that may possibly cause aortic dilation and dissection. Also, 
CAS could impose excessive ventricular load leading to ventricular wall thickening, thus 
putting an individual at a higher risk of heart attack or stroke. These pathophysiological 
effects of CAS are highly dependent on the degree of calcification. However, the impact 
of CAS development on aorta flow and left ventricular workload remains largely unknown. 
Hence the objective of this study is to measure experimentally the effect of CAS on aorta 
hemodynamics using particle image velocimetry; and left ventricular function in terms of 
left ventricular work, at different stages of calcification.  This study will provide insights 
on aorta flow abnormalities and left ventricular overload, due CAS, which can be linked to 
aortopathy and heart failure. 
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CHAPTER 1: 
INTRODUCTION 
1.1 The Human Heart 
The heart is the primary muscular organ of the cardiovascular system which acts 
as a circulatory pump and helps in driving blood throughout the vasculature. The right 
side of the heart pumps blood through the lungs where it gets oxygenated. This 
oxygenated blood enters the left side of the heart, which supplies it to the rest of the 
body. 
 
1.1.1 Anatomy  
The heart is divided into four chambers (Figure 1) [1]: the two atria (right and 
left) and two ventricles (right and left) [2]. The atria and the ventricles are connected by 
the atrio-ventricular valves (mitral and tricuspid valve), while the semilunar valves (aortic 
and pulmonary valve) connect the ventricles to their respective attached arteries (Figure 
1). The atrio-ventricular valves and the semilunar valves are responsible for maintaining 
unidirectional flow throughout the cardiac cycle. 
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1.1.2 Function  
The cardiac cycle is divided into two phases: systole and diastole. During the 
diastolic phase, (see Figure 2) the atrio-ventricular valves open and the blood flows 
passively from the atria into the ventricles, filling up to 80% of their end diastolic 
volume. The remaining 20 % is filled due to atrial contraction. The end of diastole is 
marked by the closing of the atrio-ventricular valves. The systolic phase begins with 
isovolumetric contraction of the ventricles with all the valves remaining closed. This 
causes the pressure in the ventricles to rise above the pressure in the arteries. A negative 
pressure gradient is generated across the semilunar valves causing them to open and 
Figure 1:Schematic diagram of the heart. The arrows 
represent the direction of the blood flow. De-oxygenated 
blood from the right ventricle enters the lungs via the 
pulmonary artery and gets oxygenated. Oxygenated blood 
in the left ventricle is supplied to the e entire body via the 
aorta. 
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blood to flow to the arteries. At the end of systole, all the valves close, the ventricles 
relax, and ventricular pressure progressively decreases back to 0 mmHg. The entire 
cardiac cycle lasts for 0.86 seconds for a physiological heart rate of 70 beats every 
minute.  
 
The left ventricle of the heart is responsible for supplying oxygenated blood to the 
systemic circulation through the aorta. To achieve this, the left ventricle contracts, 
creating a peak-systolic pressure of about 120 mmHg to overcome the resistance of the 
systemic vasculature. Left ventricular function is assessed using two metrics: cardiac 
output (CO) and ejection fraction (EF). CO is the amount of blood pumped by the heart 
per minute. It is calculated as the product of the stroke volume and the heart rate [2]. EF 
is a measurement of the percentage of blood that is ejected by the ventricle of its total 
blood volume at each contraction. An adult human body has typically a CO of 5.0 L/min 
and an EF of 60 % [2] 
Figure 2: Schematic showing heart valve function during systole and diastole 
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1.2  The Left Ventricle 
1.2.1 Anatomy 
The left ventricle ( Figure 3) [3] is one of the four chambers of the heart. It is 
located in the lower left portion, below the left atrium. The left ventricular chamber is 
connected to the atrial chamber via mitral valve, that regulates unidirectional blood flow 
from the atrium into the ventricle. Since it supplies blood throughout the systemic 
vasculature, the left ventricle has the most muscular walls of all the chambers [4]. The 
left ventricular wall is three times thicker that right ventricular wall. It is separated from 
the right ventricle by interventricular septum [5].  
The left ventricle is longer and more conical in shape than the right [6]. The cross 
section of its cavity is oval or nearly circular in shape. The inner surfaces of the left 
ventricle feature irregular muscular columns called trabeculae carnea [5]. Out of the three 
types of trabeculae carnea, the third type musculi papillares gives rise to chordae 
tendinae. There are two musculi papillares, that are connected to the anterior and 
aortic valve 
mitral valve 
chordae tendinea 
papillary muscle 
trabeculae carnea  
interventricular 
septum 
Figure 3:  Left ventricular anatomy. Figure shows cross section of the 
left ventricle along the coronal plane. 
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posterior wall of the left ventricle. The chordae tendinae arising from each of the 
papillary muscle are further connected to both the cusps of the mitral valve (bicuspid  
 
1.2.2 Function 
The left ventricle undergoes contraction during the systolic phase and relaxation 
during the diastolic phase of a cardiac cycle. As the left ventricle contracts, it pushes the 
oxygenated blood through the aortic valve in to the AA and supplies blood to the 
systemic vasculature. During the diastolic phase, the left ventricular muscles are relaxed 
and allow for left ventricular filling with blood. The left ventricle generates a pressure of 
120 mmHg at the peak systolic phase of the cardiac cycle. 
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1.3 The Aortic Valve  
1.3.1  Structure and Function 
The aortic valve (Figure 4) is located between the left ventricular outflow track 
and the ascending aorta (AA). The function of the aortic valve is to allow unidirectional 
flow between the left ventricle and the aorta. The normal aortic valve , also called 
tricuspid aortic valve (TAV), is composed of three leaflets (left-, right- and non-coronary 
leaflets), each attached to its respective sinus [7]. The sinus region consists of three 
cavities through which originate the left- and right-coronary arteries. The leaflets derive 
their respective names from these arteries [7], [8].  
The leaflets consist of three different layers: the fibrosa (with circumferentially 
aligned collagen fibers), the spongiosa (loose, watery connective tissue containing 
glycosaminoglycans) and the ventricularis (with radially aligned elastin fibers intertwined 
with collagen fibers) [7]–[9]. The fibrosa on the aortic side of the leaflets contributes in 
resisting the tensile stress (Figure 5) [10]  in the circumferential direction [11]. The 
left-
coronary 
leaflet 
right-
coronary 
leaflet 
non-
coronary 
leaflet 
Figure 4: Schematic of the aortic valve as seen from the 
aorta 
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ventricularis is the ventricular side of the valve cusp and helps in reducing the radial 
strains caused by the blood flow when the valve is open. [11]–[13]. The spongiosa lies 
between the fibrosa and the ventricularis and functions as a lubricating interface between 
the two other layers [10], [12].  
Figure 5: aortic valve leaflet and its mechanical response during systole 
and diastole (a) stress-strain plot for elastin and collagen fibers 
throughout the cardiac cycle, (b) leaflet orientation during systole and 
diastole  
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1.3.2 Hemodynamics 
The dynamics of aortic valve leaflet is controlled by the transvalvular pressure 
gradient established between the left ventricle and the aorta. The pressure in the aorta at 
the end of diastole is around 80 mmHg. During the systolic phase, the left ventricle 
generates a blood pressure of up to 120 mmHg, which creates a negative pressure 
gradient across the aortic valve, causing the leaflets to open. As the ventricle relaxes, a 
positive pressure gradient is created across the valve, causing the leaflet to close.  
 
 
The aortic valve maintains a unidirectional blood flow with minimum resistance. 
Figure 6: The left ventricular and aortic pressure 
waveforms. The initial systolic phase is marked with 
iso-volumetric ventricular contraction. A negative 
transvalvular pressure gradient causes the aortic valve 
to open, thus marking the beginning of ventricular 
ejection. The systolic phase ends with ventricular 
relaxation and closing of the aortic valve. 
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The blood flow behavior downstream of the aortic valve is highly dependent on the aortic 
valve size or the effective orifice area (EOA). The EOA is the minimum cross-sectional 
area of the jet emanating from the aortic valve. It is used to define the severity of valvular 
stenosis. 
As shown in Figure 6, the ventricular contraction and relaxation facilitates the 
opening and closing of the aortic valve. Along with the pressure difference, the vortices 
formed in the sinus region behind the aortic valve leaflets also facilitate the closing of the 
valve cusps. Yoganathan et al. carried out an in vitro flow study through polymeric 
valves in a left heart simulator and demonstrated that the flow structure downstream of 
the aortic valve was characterized by a central orifice jet [14]. The results also 
highlighted the existence of a vena-contracta, defined as a contracted portion of the jet 
near the valve orifice. A flow separation region was observed downstream of the valve, 
that caused reversed flow adjacent to the aortic wall. Additionally, vortices were 
observed to be trapped within the sinus regions of the aorta model. The central orifice jet 
had a maximum peak systolic velocity of 2.8 m/s.  
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1.4 Calcific aortic stenosis 
1.4.1 Epidemiology and pathogenesis 
Calcific aortic stenosis (CAS) is the most common valvular disease in the aging 
population of the developed world. It is defined as a slow progressive disease with a 
disease continuum that starts from mild valve thickening to severe calcification of the 
leaflets. The initial stage of CAS, aortic sclerosis, is characterized by slow progression of 
fibrocalcific remodeling and thickening of the valve leaflets, without any significant 
obstruction to cardiac flow. Over the years, the disease progresses to severe calcification 
causing impaired leaflet motion and serious obstruction to blood flow [15], [16]. 
In CAS, the valve leaflets become thick, stiff and covered with calcific nodules on 
the fibrosa. The aortic valve orifice is narrowed with restricted motion of the leaflets, thus 
obstructing blood flow [17]. A decrease in the valve orifice diameter leads to an 
increased pressure gradient across the valve. This triggers the left ventricle to generate 
more work to fulfill the excess of energy requirement [18], leading to progressive left 
ventricle hypertrophy and heart failure [19]. Since the onset of CAS typically occurs in 
the 6th or 7th decade of the human life, it was initially described as a degenerative disorder 
due to leaflet wear and tear and passive calcium deposition [16], [20]. However, recent 
histopathological and clinical studies have demonstrated the active nature of CAS [21], 
by defining it as multifaceted disease condition involving lipoprotein deposition, chronic 
inflammation, osteoblastic transition of valve interstitial cells and active leaflet 
calcification [20].  
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CAS is the third most common cardiovascular disease after coronary artery 
disease and systemic arterial hypertension [15], [20], [22]. The disease can be 
symptomatic or asymptomatic. The patients are likely to suffer from angina, syncope or 
complete heart failure. Once these symptoms show up, it is difficult to predict the course 
of the disease, and in severe conditions, patient death is likely to occur in a couple of 
years [13]. CAS is a slow progressive disorder. About 1.8-1.9% of the patients suffering 
from aortic sclerosis (initial stage) advance towards the latter stage of CAS, which is 
aortic stenosis [23]. Hence, when compared with aortic sclerosis, the prevalence of aortic 
stenosis (AS) is much lower. While 25% of the population above 65 years of age suffers 
from aortic sclerosis, AS is found only in 1.7% of this population group [24]. In the 
general population, the prevalence of AS is 0.4%. Of all the population suffering from 
AS, a slight predominance of 2% was observed in men [20]. 
Population-based studies across the US and Europe have reported an increase in 
the prevalence of CAS with an increase in age [21], [25]. According to the most recent 
American Heart Association statistics, the prevalence of moderate and severe CAS 
amongst population above 75 years is 2.8% [26]. 
 
1.4.2 Clinical management  
1.4.2.1 Diagnosis 
Symptoms of CAS are angina, syncope and shortness of breath. Physical 
examination of patients with CAS have reported with a harsh systolic murmur. The onset 
of these symptoms along with a systolic murmur indicate the presence of 
hemodynamically significant aortic stenosis.  
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Echocardiography is an important diagnostic tool in determining the presence of 
CAS [27]. It helps in identifying the severity of valvular obstruction [28], [29]. 
Echocardiographic images of stenotic valves have shown presence of calcific lesions on 
the valve leaflets. Continuous wave doppler echocardiography helps evaluate the peak 
blood flow velocities across the aortic valve [15] . Cardiac catheterization is another 
diagnostic tool for the assessment of CAS. This technique evaluates the transvalvular 
pressure gradient by simultaneously measuring left ventricular and aortic pressure, either 
with single dual-lumen catheter or two separate catheters [30]. 
The severity of CAS can be determined by evaluating the effective orifice area 
(EOA) of the aortic valve, jet stream velocity and transvalvular pressure gradient. The 
following (Table 1) [31] classifies aortic stenosis based on guidelines provided by the 
American Heart Association (AHA).  
 
Table 1: Parameters and criteria for assessment of CAS severity  
 Jet Velocity 
(m/s) 
Avg. Pressure 
Gradient (mmHg) 
EOA (cm2) 
Mild Stenosis <3.0 <25 >1.5 
Moderate Stenosis 3.0-4.0 25-40 1.0-1.5 
Severe Stenosis >4.0 >40 <1.0 
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The EOA of a stenosed valve is determined by using the Gorlin equation, 
mathematically expressed as: 
𝐸𝑂𝐴 =  
𝐶𝑂
𝐻𝑅 ∗ 𝑆𝐸𝑃 ∗ 44.3 ∗ √∆𝑃
, 
where CO is the cardiac output in ml/min, HR is the heart rate in beats/min, SEP is the 
systolic ejection period in seconds per heart beat and ΔP is the transvalvular pressure 
gradient in mmHg. 
 
1.4.2.2 Treatment 
To date, the management of aortic stenosis has been limited to the surgical 
replacement of the aortic valve. Medical treatments have proved to be ineffective in 
preventing or delaying the progression of the disease [10], [15], [30], [32]. Another 
procedure to treat CAS is balloon valvotomy. Balloon valvotomy is a transcatheter 
procedure in which a balloon is positioned within the aortic valve. The balloon is then 
inflated causing an increase in the valve orifice area and improved leaflet mobility [30]. 
However, this method provides temporary relief, with patients showing signs of re-
stenosis in 6-12 months and cannot be an alternative to aortic valve replacement (AVR) 
[10]. Thus, balloon valvotomy is used in patients who are at serious risk for surgery and 
waiting for an AVR [33]. 
Surgical intervention to replace the diseased aortic valve with a prosthesis has 
proved to be an efficient treatment for CAS [27], [30]. Patients with post-AVR surgeries 
have experienced a prolonged life with significant improvement in health [27]. A variety 
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of prosthetic valves have been designed in an effort to mimic the native aortic valve. In 
an AVR surgery, the native aortic valve is first excised and then replaced with an 
artificial valve by suturing it to the annulus. The choice of valve (mechanical or bio-
prosthetic) is highly patient-specific and depends on age, history of heart surgery, co-
existing organ disease and a variety of other factors. The types of prosthetic valve are 
discussed below. 
 
• Mechanical valve:  
Mechanical valves have a longer lifespan as compared to bio-prosthetic valves. 
Mechanical valves are found to last as long as 25 years and are less frequently replaced 
when compared to bio-prosthetic valves [10]. There are three design types (Figure 7) 
[13]: ball and cage, mono-leaflet and bi-leaflet. Ball and cage valves (Figure 7a) have a 
ball made out of silicon, a circular sewing ring and a cage formed by three metal arches 
[34]. The cage was initially made from Lucite which was later changed to Stainless Steel 
and then Stellite 21. The sewing ring was made out of Teflon [13]. However, the ball and 
cage design led to increased hemolysis due to the high amount of friction that existed 
between the ball and the sewing ring. Thus, the ball and cage design is no longer used for 
AVR. However, several thousands of patients still have these valves and require a follow 
up [34].  
The ball and cage design were replaced by the tilting disc valve (Figure 7b). The 
single leaflet was secured by a lateral or central metal strut [34]. The disc opened at an 
angle of 60⁰-80⁰ resulting in orifices of two different sizes. This valve was made from a 
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hemo-compatible material called pyrolytic carbon (PyC). However, it was prone to 
design failure as the struts could not withstand the mechanical load during the closing of 
the leaflet [13].  
The most common mechanical valve design is the bi-leaflet mechanical valve 
(Figure 7c). The bi-leaflet mechanical valve consists of 2 semilunar flaps made from PyC 
that are hinged to a rigid valve ring [10], [35]. The leaflets open with a 75⁰-90⁰ angle 
relative to the plane of the annulus. Once open, the two leaflets create three different 
orifices: a narrow slit like opening located between the two leaflets when open, and two 
large semicircular orifices on either side of the central opening. The bi-leaflet valve 
design is associated with recirculation and increased levels of shear stresses that led to 
hemolysis and thrombus formation [36]. As a result, patients with mechanical valves 
require a lifetime anticoagulation therapy.  
 
• Bio-prosthetic valve: 
Bio-prosthetic valves (Figure 8) [13] are made of porcine tissue or bovine pericardium 
and are designed to mimic the native aortic valve [34]. Bio-prosthetic valve are classified 
Figure 7: Different types of mechanical valves: (a) Ball and cage valve (Star-
Edwards); (b) tilting disc valve (Medtronic); (c) bi-leaflet valve (St. Jude)  
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as stented or stentless. A stented valve has a metal wire structure that is folded in a way 
to form three spikes that act an attachment site for the commissures of the valve. The 
entire wire frame is covered with Dacron to enable suturing of the tissue onto the stent 
[10]. Stentless valves are manufactured from whole porcine aortic valves or from bovine 
pericardium. These valves have improved valve hemodynamics as they provide a better 
EOA due to the absence of stent.  
Unlike mechanical valves, bio-prosthetic valves do not lead to hemolysis or 
thrombus formation and hence do not require anticoagulation therapy. However, they 
have a shorter lifespan as they are prone to calcification and structural failure due to 
mechanical stresses.  
 
• Transcatheter aortic valve replacement 
Transcatheter aortic valve replacement (TAVR) (Figure 9) [37] is a minimally 
invasive procedure used to replace a stenotic aortic valve [38]. About 33% of patients 
above 75 years of age who are suffering from CAS are turned down for AVR surgeries as 
surgical intervention is considered a potential risk for these patients [10]. TAVR is an 
Figure 8: Bio-prosthetic valves: (a) Medtronic Hancock® porcine valve; (b) 
Carpentier-Edward PERIMOUNT Magna Ease Aortic Heart Valve and (c) 
Edwards Prima plus Stentless Porcine Bio-prosthesis [13] 
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option for the patients at risk from surgical AVR. In this procedure, a fully collapsible 
replacement valve is delivered to the aortic valve site with the help of a catheter. The 
catheter is inserted through the femoral artery or through the ribs from the apex of the left 
ventricle. Once in position, the replacement valve is expanded by pushing the native 
aortic valve out of the way [39].  
 
1.4.3 Aortic complications 
The aorta (Figure 10) [40] is the largest artery that stems from the left ventricle 
and extends all the way down to the abdomen [41]. It is divided into the thoracic aorta 
and the abdominal aorta. The thoracic aorta is further divided into four parts: the aortic 
root (which includes the aortic valve annulus, the aortic valve cusps and sinuses of 
Valsalva), the ascending aorta, the aortic arch and the descending aorta [42]. The wall of 
the aorta is composed of three layers: tunica intima, tunica media and tunica adventitia 
Figure 9: Implanting transcatheter aortic valve through a femoral artery. 
The catheter navigates through the arch of the aorta, once in place, the 
fully collapsible valve expands and regulates the blood flow. 
18  
[42]. The tunica intima is composed of endothelial cells, and this is the layer, in direct 
contact of the blood. The tunica media consist of elastic fibers and smooth muscle cells. 
The tunica adventitia is the outermost layer and mainly composed of collagen. 
 
1.4.3.1 Aortic dilation 
Aortic dilation (Figure 11) [43] is defined as an abnormal expansion of the aorta. 
A normal diameter for the ascending aorta (AA) ranges between 20 and 37 mm [44]. The 
size of the AA depends on age, sex and indexes of body size. An AA can be defined as 
dilated if the diameter is 1.1 times the diameter of a normal aorta [44]. The incidence of 
AA dilation is 5-10 patients per 100,000 patients with peak incidence between 60-70 
Figure 10: Sections of the thoracic and abdominal aorta. 
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years of age [45]. The Centers for Disease Control and Prevention rank aortic dilation as 
the 15th most common cause of death in patients above 65 years of age [46]. AA dilation 
is of two types: symmetric and asymmetric. The symmetric pattern is associated with AA 
of calcified TAV and is present in the mid-ascending aorta [47] . The expansion rate of 
dilated AA ranges between 0.75- 1.1 mm/year. Aortic dilation if not addressed can lead 
to dissection and rupture of the aorta. 
 
1.4.3.2 Aortic dissection 
Aortic dissection occurs when the inner layer of the aorta tears, causing the blood 
to flow in between the tissue layers of the aortic wall. This results in abnormal pressure 
over the aortic wall and may cause it to rupture. This is a potentially dangerous condition 
that needs immediate medical attention.  
Figure 11: Symmetric pattern of 
aortic dilation in TAV AA. 
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Aortic dilation has been associated with aortic dissection. Numerous studies have 
attempted to evaluate the risk of aortic dissection with the diameter of a dilated AA. 
Aortic diameter of 5.5 cm or greater [42] was considered as a risk for aortic dissection, 
however a clinical study involving 230 patients reports occurrences of rupture in dilated 
AA with diameters less than 5.5 cm [48]. Hence it is important to monitor the progression 
of aortic dilation. This can be done using imaging techniques such as computed 
tomography (CT) scan and magnetic resonance imaging (MRI) [44].  
 
1.4.3.3 Management 
Management of aortic dilation involves taking preventive measure to avoid 
dissection of the dilated aorta. This is achieved by surgical intervention or by using 
minimally invasive techniques. Surgical treatment for aortic dilation involves an open 
chest approach. It involves removal of the aorta tissue damaged due to dilation and 
replacing it with a fabric tube, called graft [49]. An alternative for surgery is a minimally 
invasive technique called endovascular repair for treating dilation [44]. In this technique, 
a catheter with an expandable stent graft is inserted through one of the groin arteries and 
is guided to the site of dilation with the help of X-ray images. The stent graft is allowed 
to expand within the aorta, while the wireframe pushes against the healthy part of the 
aorta sealing the graft in place [50]. The blood then flows through the graft and does not 
come in contact with the dilated region of the aorta. 
 
1.4.4 Left ventricular hypertrophy 
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 Left ventricular hypertrophy can be defined as an enlargement and thickening of 
the myocardial mass [21], [51]. Aortic stenosis has been associated with left ventricular 
hypertrophy [51]. In aortic stenosis, the reduced valve orifice, causes an obstruction to 
the blood flow. To overcome this obstruction the left ventricle overworks to maintain the 
cardiac output. This is achieved by an increase in ventricular pressure. The mechanical 
signals generated by the elevated ventricular pressure initiates a cascade of biological 
events that lead to an increase in cardiac mass [15].  Treatment for left ventricular 
hypertrophy due to aortic stenosis involves replacement of the stenosed valve with an 
artificial or tissue valve [51]. 
  
Figure 12: Figure shows sectional view of the heart with left 
ventricular hypertrophy 
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1.4.5 Evidence for a hemodynamic etiology 
1.4.5.1 Aorta hemodynamics 
Clinical findings have established a relation between aortic dilation and TAV 
associated stenosis. More than half of the patients suffering from CAS also have a dilated 
ascending aorta (AA) [52]. Mid-ascending aortic dilation in patients suffering from CAS 
is now accepted as purely hemodynamic due to TAV stenosis [53], [54]. Crawford and 
Roldan carried out a study that assessed the aortic root diameter of 118 patients suffering 
from aortic stenosis. The study concluded that aortic root dilation is common in patients 
with aortic stenosis. Another study assessed the rate of expansion in patients with post-
stenotic dilated AA that were submitted for AVR surgery. Ninety-three patients suffering 
from isolated severe CAS along with dilated AA (50-60 mm) were involved in this study 
[52]. AVR surgery was performed and the patients had a follow-up for about 10 years. 
The follow-up was performed using CT scans and echocardiographic evaluations. During 
the 10 years, there was no significant increase in the aortic dimensions with an average 
expansion rate of 0.3 ± 0.2 mm/year [52]. Studies that have tracked post-stenotic aortic 
dilation with no valve replacement, have reported rate of expansion 10 times the rate 
being reported in this study [55], [56]. This study highlighted two major findings: 1) once 
the hemodynamic conditions were corrected by replacing the stenotic valve, no further 
expansion of the aorta was observed, 2) hemodynamic effect of valvular stenosis is the 
reason for post-stenotic aortic dilation.  
Turbulent flow is believed to cause a variety of pathophysiological effects. 
Viscous Shear stresses due to turbulent flow are believed to cause damage to the intimal 
surface of the blood vessels. The existence of turbulence in the aorta was demonstrated 
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by a clinical study involving 15 people, that analyzed the flow in the AA of humans with 
normal and diseased aortic valves [57]. The study highlighted that the maximum 
turbulence was observed in AA of patients with aortic stenosis. Histological studies of 
aortic wall from the post stenotic region have shown defective elastic elements and 
extensive areas of increased fragility [54]. 
An in vitro study by Yearwood et al analyzed the flow in a human aorta model 
using laser Doppler anemometer (LDA) [58]. In this study, aortic stenosis was modeled 
using prosthetic aortic valves attached to an acrylic aorta model in a mock circulatory 
system. Turbulent axial stresses determined in this study were found to increase 
drastically with increased stenosis. Another in vitro study by Yoganathan et al, found 
hemodynamics downstream of the stenosed aortic valve, to be dependent on the degree of  
stenosis [59]. 
A recent clinical study using 4-D flow magnetic resonance imaging (Figure 13), 
provided new insights on the effect of aortic stenosis on regional aortic wall shear stress 
(WSS) [60]. Patients with moderate and severe stenosis, with an impaired valve opening 
experienced increased velocities in the AA. For patients with mild aortic stenosis, a 57 % 
increase in the WSS was observed in the outer proximal aorta, when compared with the 
normal TAV patients. Further, elevation in WSS was observed in patients with moderate 
and severe aortic stenosis (20-178%) when compared to patients with no stenosis. The 
patient cohort of this study involved patients with RL-BAV (bicuspid aortic valve (BAV) 
with left and right coronary leaflet fusion), NL-BAV (BAV with left and non-coronary 
leaflet fusion), TAV, and their stenosed counterparts with degrees of stenosis, ranging 
from mild -severe. This study highlighted that the variability and magnitude of 3D WSS 
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patterns is significantly higher in patients with aortic stenosis, irrespective of the valve 
phenotype. This study contradicts the previous findings that aortic stenosis did not 
elevate WSS [61], by demonstrating a significant increase in aortic 3-D WSS in the 
presence of aortic stenosis for both BAV and TAV groups.  
  
Figure 13: WSS analysis using 4-D MRI. Figure shows elevated WSS in AA 
with stenosed aortic valves 
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Elevated WSS has been previously related to pathogenic vascular remodeling that 
leads to aneurysm [62]. Thus, all of these clinical, imaging, in vitro and in vivo studies 
seem to provide compelling evidence for a possible role of hemodynamics in post-
stenotic AA dilation. 
 
1.4.5.2 Calcified valve hemodynamics 
In vitro experiment, assessing the effect of varying degrees of aortic stenosis on 
pulsatile  valvular flow, was conducted by Bluestein et al. using laser doppler 
anemometry (LDA) [63]. The study was conducted using polyurethane valves. The 
different degrees of stenosis were mimicked by gluing the leaflets together, to generate a 
smaller orifice. The results demonstrated a noticeable effect of aortic stenosis on the 
velocity profile with elevated turbulence level when compared to that of normal aortic 
valve.  
Another flow visualization study using PIV was conducted to analyze the flow 
differences downstream of a normal and calcified aortic valve [64]. High orifice jet 
velocity and regions of increased viscous stresses accompanied by high turbulence 
downstream of the calcified valves were observed. With increased velocities observed at 
peak systole in calcified valves, high magnitudes of vorticity were observed between the 
sinus wall and the leaflets. 
A computational study using fluid structure interaction modeling has compared 
the flow generated by normal and calcified aortic valve (Figure 14) [65]. The healthy 
model of the aortic valve generated a peak systolic velocity of 1.57 m/s, while the 
26  
narrowed valve orifice in the calcified valves, led to an increase in peak orifice velocity. 
A significant difference was observed in the transvalvular pressure gradient, as the 
severely calcified valve model exhibited a 305% increase relative to the healthy model. 
The WSS on the leaflets was also maximum for severely calcified model. 
 
 
A clinical study evaluated the relation of left ventricular hypertrophy with systolic 
dysfunction and heart failure, in patients suffering from aortic stenosis [66]. It involved 
137 patients with aortic stenosis undergoing pre-operative echocardiography and cardiac 
catherization. The findings of this study suggest that left ventricular hypertrophy 
promotes adverse cardiac consequences and provides a pathway towards heart failure in 
Figure 14: Figure shows the velocity contours, velocity streamlines and velocity vectors for 
healthy, calcified and severely calcified valve models 
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aortic stenosis. 
 
1.5 Knowledge gap and research questions 
1.5.1 Hemodynamic etiology of CAS 
CAS has emerged as an active multifaceted disease condition whose triggers 
include hemodynamic, cardiovascular and mechanical factors [67]–[69]. Studies indicate 
that abnormal hemodynamics in the vicinity of aortic valve, experienced by the valve 
leaflets cause tissue inflammation, which can lead to calcification and aortic valve 
stenosis [70] .  
The partial opening of the aortic valve due to stenosis could generate 
hemodynamic alterations downstream of the valve resulting in a chaotic and turbulent 
flow in the ascending aorta. The aorta lining in direct contact with the blood, tunica 
intima, is composed of endothelial cells (EC). EC are highly sensitive to hemodynamic 
forces and alteration in the blood flow environment have caused cell deformation, 
realignment and inflammation [71]. These altered biological responses due to changes in 
the hemodynamic environment have eventually led to aortic wall remodeling and dilation 
[71], [70], [72], [73]. These etiologies have been supported by studies that have 
demonstrated the impact of altered hemodynamics on valvular and aortic tissue [70], 
[74]–[77]. 
The aortic valve stenosis also creates an obstruction to the blood flow during the 
ventricular ejection. To overcome this obstruction and maintain the cardiac output, the 
left ventricle systolic pressure increases subjecting the ventricle to an overload. This 
28  
increase in ventricular pressure to maintain the left ventricular ejection performance, 
initiates a surge of biological events, that ultimately lead to hypertrophy of the cardiac 
muscle and myocardial fibrosis [15] 
 
1.5.2 Rationale for this study 
As suggested in vivo, CAS could cause downstream flow alterations giving rise to 
abnormal hemodynamics. The hemodynamic theory of CAS asserts that this altered 
hemodynamics in the AA could cause abnormal biological responses, affecting the 
intimal surface of the aortic wall which can lead to aortic dilation and dissection. To 
validate this theory, there is a need to investigate the degree to which aorta 
hemodynamics is altered due to aortic valve stenosis. This study aims to assess the 
isolated impact of the different degrees of valvular stenosis on aorta hemodynamics. 
The obstruction to the blood flow due to narrowing of the valve in CAS, affects 
left ventricular function. To overcome this increased resistance to blood flow, the left 
ventricle performs additional work to maintain a physiological cardiac output. This 
overload causes adverse cardiac consequences in the form of ventricular hypertrophy, 
increase in ventricular mass that eventually lead to heart failure. Hence it is necessary to 
quantify the amount of overload imposed by valvular stenosis on the left ventricle.  This 
study investigates the effect of varying degrees of valvular stenosis on left ventricular 
overload.  
Many studies have assessed the impact of stenosis on aorta hemodynamics. In 
vitro study using LDA [63] assessed the impact of stenosis on aorta flow. However, the 
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study incorporated polyurethane valve models and a non-compliant aorta model, which 
could not generate native valve hemodynamics. Also, stenosis was modelled using glue 
lesions which questioned the accuracy of the results. To mimic the native valve 
hemodynamics another LDA study [78] used bio-prosthetic valves to assess the effect of 
valvular stenosis on aorta flow. However, the aorta model used was heavily simplified as 
a straight cylindrical non-compliant conduit. Lastly, PIV studies have assessed the impact 
of valvular calcification on the flow in the sinus region using porcine tissue valves [64], 
and the effect of congenitally defective valves on flow in AA [79], but the impact of  
calcific aortic stenosis on flow in the AA remains largely unknown.  
Clinical flow visualization technique such as MRI is able to measure wall shear 
stress abnormalities caused by valvular stenosis in the AA [60]. However, most MRI 
studies have been performed in patients with pre-existing AA dilation, preventing the 
isolation of the effects of valvular stenosis on AA hemodynamics. Limited spatial 
resolution is another drawback of PC-MRI.  Computational studies allow higher spatial 
resolution. However, these studies have significant simplification in terms of geometry 
and cannot assess the impact of turbulence on the flow field. 
Clinical studies have associated  ventricular overload due to valvular stenosis to 
ventricular remodeling and  hypertrophy [66], [80]. However, the amount of overload 
imposed on a ventricle due to a stenosis has not been quantified. 
Therefore, this study aims at providing insights on the isolated impact of valvular 
stenosis on ascending aortic flow using a non-dilated compliant silicon aorta model and 
left ventricular function
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CHAPTER 2: 
SPECIFIC AIMS 
CAS is the most prevalent type of heart valve disease and is characterized by the 
formation of calcific nodules on the valve leaflets, resulting in the narrowing of the valve 
orifice. Valvular stenosis is associated with two cardiovascular complications: aortic 
dilation and left ventricular hypertrophy. The hemodynamic theory of valvular stenosis 
infers that the structural changes in the valve generate flow abnormalities downstream of 
the valve in the AA. These altered hemodynamics could  affect the aorta lining in 
immediate contact with the blood surface (endothelium), triggering adverse biological 
responses [73] and compromising the structural integrity of the aortic wall which could 
possibly lead to aortic dilation and dissection [81]. Therefore, it is necessary to determine 
the extent to which the varying degrees of stenosis alter the hemodynamics in the 
ascending aorta. CAS causes reduced valve orifice. The narrowing of the aortic valve can 
possibly create serious blockage to the blood emanating from the left ventricle. To 
overcome this obstruction and maintain a physiologic cardiac output, the left ventricle 
has to work harder thus experiencing an additional workload. This increase in ventricular 
overload may lead to the thickening of the muscle wall and increase in ventricular mass. 
This condition is defined as left ventricular hypertrophy, which puts an individual at a 
higher risk for a heart attack or stroke. Hence it is important to assess the degree to which 
valvular stenosis creates additional workload on the left ventricle. 
2.1  Hypothesis and Objective: 
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The hypothesis of this study is that structural changes in the aortic valve due to 
CAS can cause abnormal hemodynamics in the aorta and left ventricular overload. The 
magnitude to which aorta hemodynamics and ventricular load is altered, highly depends 
on the degree of valvular stenosis. Hence the objective of this study is to experimentally 
quantify the impact of valvular stenosis on aorta hemodynamics and left ventricular 
function in a degree dependent manner. This objective is addressed through three specific 
aims. Aim 1 describes the design of an experimental left-heart simulator and setup of a 
flow visualization technique called particle image velocimetry (PIV), required to 
investigate the hypothesis. The other two aims address the hypothesis through their 
respective objectives: to evaluate the impact of valvular stenosis on aorta hemodynamics 
(aim 2) and left ventricular function (aim 3). 
 
2.2  Specific Aim 1:  To design an in vitro setup that mimics a physiological flow    
in the left side of the heart and captures the flow using PIV.  
The objective of this aim was to design a setup that allowed the assessment of the 
hemodynamic environment downstream of porcine aortic valve models in the AA. The 
flow on the left side of the heart is pulsatile due to the periodic contraction and relaxation 
of the left ventricle. Hence a pulsatile flow loop was needed to replicate the physiological 
ventricular and aortic pressures (0-120 mmHg, 80-120 mmHg) and cardiac output (5.0 
L/min). The flow loop designed was validated against physiological aortic pressure and 
flowrate waveforms. A flow meter and pressure transducers allowed measurement of 
flowrate and ventricular and aortic pressures. Flow analysis was done using PIV. The 
PIV setup included a laser to illuminate the flow field of interest and a high-speed camera 
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to capture images.  
 
2.3  Specific Aim 2: To assess the effect of valvular stenosis on aorta 
hemodynamics.  
In this aim, PIV was used to capture velocity flow fields downstream of the valve, 
near the sino-tubular junction as well as the AA. Velocity flow fields were captured at 43 
phases of the cardiac cycle and ensemble averaging was done over 100 cardiac cycles at 
each phase. Along with the velocity flow field, vorticity, viscous shear stress, Reynolds 
shear stress and turbulent kinetic energy were evaluated from the velocity fields to 
compare aorta hemodynamics downstream of a normal TAV tissue model and two 
stenotic models mimicking moderate and severe calcification.  
 
2.4  Specific Aim 3: To assess the effect of valvular stenosis on left ventricular 
function.  
This aim tries to evaluate the impact of the degree of valvular stenosis on the 
overload imposed on the left ventricle to maintain a physiologic cardiac output. Left 
ventricular work was evaluated by measuring pressure-volume relationships during the 
ejection phase for the normal TAV and the two stenotic models.  
33  
 
 
CHAPTER 3: 
MATERIALS AND METHODS 
3.1 Flow loop description 
A flow loop was constructed to mimic the hemodynamics of the left side of the 
heart. At 70 beats per min with a cardiac cycle 860 ms long, the flow conditions expected 
were pulsatile and periodic, with a desired flow rate at a given instant of time ranging 
between -5 to 20 L/min and a cardiac output (CO) of 5 L/min. The pulsatile flow loop 
consisted of a bath chamber, a flow meter, a compliance and resistance units and a 
reservoir (Figure 15). The flow was driven by a pulse generator that delivered 
compressed air (25 psi) to a diaphragm accumulator (AD140B25T9A1, Parker Hannifin, 
Cleveland, OH) mimicking the left ventricle (Figure 16). The operation of the ventricular 
chamber was controlled by a 2-position 3-way solenoid valve (56C-13-111CA, Mac 
Valves, Wixom, MI). The opening and closing of the solenoid valve was timed using a 
square wave signal generated by a LabVIEW (National Instruments Corp., Austin, TX) 
virtual instrument (VI). Unidirectional flow through the loop was achieved by installing a 
mechanical valve in the mitral position upstream of the ventricular chamber, and a 
porcine aortic valve downstream of the ventricular chamber. 
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Figure 15: Pulsatile flow loop with PIV setup. (a) schematic of flow loop 
highlighting all its components and (b) picture of laboratory setup of the flow 
loop. 
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A fluid reservoir (volume: 4 L) placed between the resistance unit and the mitral 
valve functioned as the left atrium and supplied fluid to the ventricular chamber during 
diastole. Resistance and compliance units were used to achieve desired control over the 
pressure and flow conditions. Compliance is defined as the ability of a blood vessel to 
distend and increase in volume with increase in pressure. Mathematically, compliance C 
can be quantified as 
𝐶 =  
𝛥𝑉
𝛥𝑃
, 
Figure 16: Diaphragm accumulator 
mimicking left ventricular function. 
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where 𝛥𝑉 is the change in the arterial volume and 𝛥𝑃 is the change in the arterial blood 
pressure. The compliance chamber (Figure 17) was a cylindrical chamber consisting of a 
piston that controlled the ratio of air to fluid inside the chamber.  
 
A gate valve (Figure 18) was used to generate vascular resistance and to control 
mean arterial pressure (MAP). The systemic vascular resistance (R) is the resistance to 
the blood flow created by the systemic vasculature. It can be defined mathematically 
using the Hagen-Poiseuille flow theory as 
𝑅 =  
𝛥𝑃
𝑄
, 
where ΔP is the change in the time averaged pressure across an arterial segment and Q is 
Figure 17: Compliance chamber 
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the averaged arterial flow rate. 
 
 
Piping used in the pulsatile loop was constructed using PVC and silicon tubing. 
Two pressure transducers (P55D Validyne Engineering Corp., Northridge, CA) were 
used to measure the aortic and ventricular pressure. The instantaneous flow rate 
generated by the loop was measured by an ultrasonic flowmeter (ME-19-PXN, 
Transonic, Ithaca, NY) installed downstream of the ventricular chamber. The flow loop 
was tuned using the compliance and resistance units until a physiological cardiac output 
of 5.0 L/min and an approximate value of aortic pressure was achieved.  
 
 
 
Figure 18: Gate valve used to control systemic 
resistance 
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The pressure transducers (Figure 19b) and flow meter (Figure 19a) generated 
voltages which were analyzed by their respective modules. These modules sent analog 
signals to a Data Acquisition Board (DAQ) (National Instruments Corp., Austin, TX) 
(Figure 19c). A digital signal was generated by the DAQ board to monitor the pressure 
and flow rate waveforms in real time using a secondary VI. This VI also recorded the 
time history of instantaneous flowrate, and ventricular and aortic pressures. The flowrate 
and pressure values obtained were ensemble averaged.  
 
 
 
 
Figure 19: Figure showing components of the flow loop. (a) ultrasonic flowmeter (b) 
pressure transducers on the aorta and the ventricular side (c) data acquisition board 
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3.2 Test section 
 
The porcine aortic valve was placed into a valve chamber made of acrylic with 
flat external walls to minimize refraction of the incident laser sheet. The chamber 
consisted of an idealized three-lobed sinus geometry and a straight cylindrical conduit 
(inner diameter: 24mm, length: 20 mm) mimicking the proximal section of the ascending 
aorta. Pressure transducers were installed into two ports placed 24 mm upstream and 24 
mm downstream of the aortic valve sinus, measuring the aortic and ventricular pressure 
respectively. The valve chamber was connected to a compliant silicone aorta model. The 
aorta geometry (Medisim Corp. Inc., Alton, ON) was 3D printed using a silicone 
material. The aorta model and the valve chamber were submerged in a rectangular bath 
chamber (Figure 20), filled with a solution of water and glycerol (BDH1172 VWR 
ANALYTICA) (water: 60% and glycerol: 40%, by volume). The properties of this 
solution (density: 1060 kg/m3, dynamic viscosity: 3.8 cp) approximated the properties of 
blood (density: 1060 kg/m3, dynamic viscosity: 3.5 cp) and provided partial index 
matching (refractive index: 1.39) with silicone (refractive index: 1.41) and acrylic valve 
chamber (refractive index: 1.49). 
The bath chamber featured an inlet port that connected to the inlet of the 
rectangular conduit and an outlet port that connected to the outlet of the aorta model. The 
rectangular conduit connected to the inlet of the valve chamber 
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3.3 Valve models 
  Three aortic valve models were constructed for this study: a normal TAV 
model (nTAV) and two stenotic models mimicking moderate (mTAV) and severe 
(sTAV) calcification. Porcine hearts were obtained from a local slaughterhouse 
(Copey’s Butcher House, Medway, OH) and were transported to the laboratory in ice-
cold phosphate buffered saline (PBS). Upon arrival, the valves were excised from the 
hearts and were kept moistened via frequent application of PBS solution. Excision 
consisted of separating the valve from the base of the aorta.  The following step 
consisted of removing the excess ventricular muscle around the sinus region and 
Figure 20: Figure of the bath chamber showing the valve chamber 
connected to the compliant silicone aorta, and the two pressure 
transducers used to measure aortic and ventricular pressures. 
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suturing the valve on the circular supporting base plate of the valve mount. To 
maximize optical access to the valve, the sinus wall was surgically removed without 
damaging the valve leaflets. All experiments were conducted within 48 hours of 
procuring the organ. 
 
3.3.1 Normal TAV model 
The normal TAV (nTAV) model (Figure 21) was constructed by removing the 
excess muscle around the valve annulus. The valve was fixed on the circular shaped 
valve mount using surgical sutures. The valve posts assisted in keeping the commissures 
in place and maintain the leaflet orientation.  
 
 
 
 
Figure 21: Figure shows (a) a normal TAV (nTAV) sutured on the 
valve mount, (b) circular metallic valve mount. 
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3.3.2 Calcified TAV models 
Calcified valve models (Figure 22) were fabricated to replicate moderate and 
severe calcification via partial commissural fusion. Once the valve was placed onto its 
circular mount, partial commissural fusion was achieved by suturing together the adjacent 
edges of the leaflets. The two degrees of stenosis were obtained by suturing the leaflets 
over a length of 4 mm (mTAV) and 8 mm (sTAV) away from the valve posts towards the 
leaflet tip, respectively. 
 
3.4     Particle Image Velocimetry  
Particle Image Velocimetry (PIV) is a flow visualization technique that measures 
instantaneous velocity flow fields by recording images of suspended seed particles in the 
flow at successive instants of time (𝑡) and ( 𝑡 + ∆𝑡). The layout of a PIV setup is shown 
in Figure 23. The first step in PIV is to seed the working fluid with tracer particles. A 
Figure 22: Pictures of stenosed valve models. (a) 
mTAV and (b) sTAV models. Picture also 
highlights the variation in the placement of sutures 
over the leaflets to mimic different degrees of 
stenosis. 
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pulsed light source and its necessary optics used to generate a thin sheet of laser 
illuminates a cross-section of the flow while a camera captures image pairs at a given 
frequency. Software and electronic equipment helps to synchronize the pulsing of the 
laser with the frame rate of the camera.  
 
 
In PIV, the velocity of the flow field is extracted from the motion of the tracer 
particles. The velocity is calculated indirectly, by measuring the displacement of the 
tracer particles in a time interval ∆𝑡 between the two successive image pairs. However, 
the displacement of the particles is not calculated on a single particle level, the flow field 
of interest is divided into smaller sections called interrogation regions or windows. The 
interrogation window is the region where cross-correlation is performed. 
The images captured by the camera in PIV are greyscale digital images. The gray 
Figure 23: Schematic showing setup and functioning of PIV. 
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level for the camera sensor is defined using bits, and the number of levels per pixel are 
evaluated as 2𝑏𝑖𝑡. In general, particle images are grayscales with a wide range of 
intensities (256 for an 8 bit camera, 65536 for a 16 bit camera). These intensity values of 
each pixel, from the first and the second image of the image pair, are used to perform 
cross-correlation.  
The flow velocity is evaluated at equidistant grid points in PIV. The interrogation 
window is centered on these grid points. Once the interrogation region is defined, the 
displacement function of the tracer particles outlining the motion of the particles from the 
first image (time 𝑡) to the second image (time 𝑡 + ∆𝑡) is calculated by a cross-correlation 
technique. The correlation value is evaluated by the number of overlapping particle in the 
spatially shifted image [82]. The location of the highest correlation value in the 
correlation plane, is interpreted as the mean displacement of the particles in that region. 
Direct cross-correlation is expensive in terms of required computing power.  Hence, the 
correlation is done using efficient fast Fourier transform (FFT) algorithm. 
The average velocity is then evaluated by dividing the mean displacement of the 
particles by the time interval ∆𝑡 between the two consecutive images. Once the velocity 
is evaluated, the center of the interrogation window is shifted to the next grid point, thus a 
two-dimensional velocity field is obtained.  
The size of the interrogation window plays an important role in the PIV 
measurements. The reliability of the cross-correlation method is highly dependent on the 
number of overlapping particles that exist between the two interrogation windows, 
centered on the same grid point of the image frames taken ∆𝑡 apart. A small number of 
overlapping particles questions the accuracy of the mean displacement evaluated. Hence 
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to maximize the accuracy of the measurements, an overlap is introduced between two 
consecutive interrogation windows. Overlap determines the grid of the velocity vector or 
the distance between the two adjacent velocity vectors. Overlap improves spatial 
resolution. PIV studies conducted have shown that a 50% or 75% overlap is common 
[82] [83].  
Advanced evaluation methods have been incorporated to improve the accuracy 
and resolution of the PIV results. PIV images can now be evaluated using a multi-pass 
algorithm. In this method, an initial estimate of particle displacement is provided by a 
large size of interrogation window. This estimate is used to displace or deform the 
interrogation region used in the next pass. This technique allows to deviate from the 
quarter rule (all displacements should lie within 1/4th of the interrogation window size), 
thus providing the use of a smaller interrogation window size and improved spatial 
resolution.  
 
3.4.1 Tracer particle deposition speed 
The assumption that particles passively follow the flow is incorrect, since the 
particles are subjected to unsteady flow effects and can possibly have a velocity relative 
to the flow. Hence it is necessary to evaluate the deposition velocity of the tracer particles 
used in the PIV setup. This can be done using the Stoke’s settling velocity of the particles 
given by:   
𝑣max  = 
2
9
 𝑟𝑝
2 (
𝜌𝑝 − 𝜌𝑓
𝜇
) 𝑔, 
where  𝑟𝑝 is the particle radius, 𝜌𝑝 is the particle density, 𝜌𝑓 is the fluid density, 𝜇 is the 
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dynamic viscosity of the fluid and 𝑔 is the acceleration due to gravity. The particles used 
in this study had a diameter of 11.7 μm and a density of 1100 kg/m3. The density of the 
working fluid was 1060 kg/m3 and viscosity of 3.8×10-3 kg/m.s. The acceleration due to 
gravity was taken as 9.81 m/s2. Thus, the tracer particle deposition speed evaluated was 
0.785 μm/s 
 
3.4.2  PIV setup 
PIV system was incorporated into the pulsatile flow loop to capture the velocity 
field in the mid-planes of the sinus and the ascending aorta regions. The tracer particles 
selected were neutrally buoyant hollow glass microspheres (Sphericel 110P8, Potters 
Industries LLC., Malvern, PA); with and average diameter of 11.7 µm and density 1100 
kg/m3. The PIV system (Flowmaster, LaVision, Goettingen, Germany) incorporated a 
double-head Nd:YAG laser (Nano S 30-30 PIV, Litron Lasers, Rugby, England) which 
generated a pulsed output laser beam (wavelength: 532 nm; max output: 300 mJ; pulse 
duration: 4ns). For each valve model, the laser sheet was positioned to illuminate two 
sections of the flow through the laser access window situated on the bath chamber. Laser 
position 1 was defined as the middle horizontal cross-section of the valve chamber, while 
laser position 2 illuminated the middle cross-section of the AA model (see Figure 24). 
The flow in the aorta was measured in two non-aligned planes so that maximum field of 
view could be attained in both regions of interest. The two sections of the flow were 
separated by a 10-mm thick stainless-steel block connecting the aorta phantom to the 
valve chamber. The optical access was blocked for this section of the flow. For each laser 
position, the camera was placed perpendicular to the laser sheet. Images at these two 
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positions were captured by Imager sCMOS camera (LaVision, Goettingen, Germany), 
resolution of 2560 × 2160, using AF Micro Nikkor 60 mm lens (Nikon Inc., Melville, 
NY) and narrow band pass filter (532 ± 10 nm). The camera was used to capture a 62 × 
47 mm section of the flow. Image acquisition was performed by dual-channel frame 
grabber, dual processor 64-bit, and 2.40 GHz computer. Image pairs were captured at 43 
phases of the cardiac cycle for each valve model and laser position. For each phase of the 
cardiac cycle, 100 image pairs were captured. A time filter was applied to remove 
unsteady laser light reflections by subtracting the minimum intensity. A sliding 
background was subtracted to overcome the intensity fluctuations in the background. This 
provided an image with constant background level without affecting the particle signal to 
be corelated. The vector filed calculated is associated with spurious or false vectors. 
These spurious vectors were removed using median filter.  In order to capture the 
variations of the average flow field, ensemble averaging was performed on these 100 
image pairs at each phase. The ∆ 𝑡 between the two image pairs was adjusted in such a 
way that the maximum average displacement of the particle was approximately 25% of 
the size of the smallest interrogation window (32 × 32 pixels). 
48  
 
 
The VI allowed to introduce a delay between the opening of the solenoid valve 
and the trigger that controlled the firing of the laser. This allowed to capture phase-locked 
PIV images that enabled to measure flow field velocity at specific phases of the cardiac 
cycle (acceleration, peak systole, deceleration and diastole). Cross-correlation was 
performed using the commercial PIV software Davis 8.3 (LaVision). A multi-pass 
scheme was implemented with an initial interrogation window of 64×64 pixels and a final 
interrogation window of 32×32 pixels. A 50% overlap was introduced between each 
window to improve spatial resolution and limit in-plane particle loss. 
 
 
Figure 24: Figure shows flow fields captured and the respective laser and camera 
positions used to capture (a) camera and laser positions to capture flow 
characteristics in the proximal and the distal AA region (b) schematic of the flow 
filed of interest. 
a b 
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3.5 Uncertainty Analysis 
An uncertainty analysis validates the PIV measurements by calculating the 
difference between actual and the measured values. PIV uncertainty can be divided into 
two different categories: systemic or bias uncertainties and random uncertainties. 
Systemic uncertainty or bias uncertainty is a fixed uncertainty associated with a specific 
system. The bias uncertainty is associated with peak-locking or pixel-locking 
phenomenon. Pixel locking will occur when the size of the particle image diameter is 
relatively smaller when compared to the size of the pixel in the camera, causing the 
velocity to be strongly biased towards the integer-pixel values. This pixel locking effect 
is unacceptable if the size of the particle image diameter is less than one-pixel unit. To 
keep the pixel locking effect to a minimum, a widely accepted particle image diameter is 
of two pixels. Also scientific complementary metal-oxide semiconductor (sCMOS) 
cameras have small pixel diameter of 5-10 μm. Random uncertainty is variable and can 
be estimated using repeated measurements. The typical causes of random uncertainty are: 
noise or cycle-to-cycle variations. This noise can be evaluated by calculating the mean 
velocity and standard deviation from ensemble averaged date sets. The random 
uncertainty is inversely proportional to the square root of the number of measurements, 
thus it is necessary to obtain adequate sample size to reduce the random uncertainty.  
 
3.6 Hemodynamic Characterization 
The in-plane instantaneous velocity fields (𝑢: axial component, 𝑣: transverse 
component) obtained by cross-correlation were first filtered to eliminate erroneous 
velocity vectors and then ensemble-averaged over 100 cardiac cycles to yield an average 
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velocity field (𝑢:̅ mean axial component, ?̅?: mean transverse component) at each phase. 
All subsequent analyses were performed in Tecplot 360 (Tecplot Inc., Bellevue, WA). 
The axial and transverse components of the velocity fluctuation field (𝑢′ and 𝑣′) were 
obtained from Reynolds decomposition, by subtracting the average velocity components 
from the instantaneous velocity components: 
𝑢′ = 𝑢 −  ?̅?, 
 
𝑣′ = 𝑣 −  ?̅?, 
Vorticity, viscous shear stress, Reynolds shear stress and turbulent kinetic energy 
were used to characterize the flow fields generated by the valve models were evaluated 
using Tecplot 360 as: 
 
?̅? =  
𝜕?̅?
𝜕𝑥
− 
𝜕?̅?
𝜕𝑦
, 
 
𝜏̅ =  𝜇 (
𝜕?̅?
𝜕𝑦
+  
𝜕?̅?
𝜕𝑥
), 
 
𝜏′ =  𝜌𝑢′𝑣′̅̅ ̅̅ ̅̅ , 
 
and 
 
𝑇𝐾𝐸 =  
1
2
(𝑢′2̅̅ ̅̅ + 𝑣′2̅̅ ̅̅ ), 
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respectively, where 𝜌 is density of blood and 𝜇 is the dynamic viscosity, and the overbar 
denotes an ensemble averaged quantity. 
  
3.7 Left ventricular overload characterization 
To calculate the left ventricular overload, a pressure-volume curve was plotted for 
each valve model. The pressure value for the ejection phase was obtained from the VI, 
while the corresponding change in the ventricular volume was evaluated from the 
instantaneous flowrate waveform. The area under the flow rate curve for the ejection 
phase (Figure 25), was evaluated to measure ventricular volume. This was done by 
dividing the area into trapezoids with the two parallel sides separated by a time step ∆𝑡, 
thus evaluating the change in the volume. The expression used to evaluate the change in 
volume: 
 
𝛥𝑉 = 0.5 × (𝐹𝑙1 + 𝐹𝑙2) × 𝛥𝑡, 
 
where  𝛥𝑉 is the change in ventricular volume, 𝛥𝑡 = 𝑡2 −  𝑡1,  𝐹𝑙1 and 𝐹𝑙2 are the 
corresponding flowrates at time  𝑡1 and 𝑡2. The sum of all the 𝛥𝑉 throughout the ejection 
phase ultimately provides the total ventricular volume  
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Once the P-V graph was plotted, the ventricular work was evaluated in Joules by 
calculating the area under the P-V curve using trapezoidal rule. The expression for work 
for a change in ventricular volume 𝛥𝑉 : 
 
𝑉𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 𝑤𝑜𝑟𝑘 = 0.5 × (𝑃1(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐) + 𝑃2(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐)) × 𝛥𝑉, 
 
where 𝛥𝑉 = 𝑉2 −  𝑉1,  𝑃1 and 𝑃2 are the corresponding ventricular pressures at 
ventricular volume 𝑉1 and 𝑉2 
Figure 25: Schematic of the flow rate ejection phase, divided into trapezoidal 
shaped areas to measure change in the ventricular volume  
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CHAPTER 4: 
SPECIFIC AIM 1 
 
The pulsatile flow loop was constructed to mimic the physiological flow in the 
left side of the human heart. The CO of approximately 5 L/ min was achieved by 
supplying the compressed air at 25 psi. The aortic and ventricular pressure waveforms 
matched the physiological values approximately.  
 
4.1 Flowrate waveform 
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Figure 26: Flowrate waveform generated by the pulsatile flow loop. 
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The average and the instantaneous flowrate generated by the flow loop was in 
good agreement with the physiological values [81]. Figure 26 shows the flow rate 
waveform spanned over one cardiac cycle. The maximum flow rate was 22.7 ± 1.73 
L/min while the minimum flow rate was -3.0 ± 0.32 L/min. The flow loop could generate 
and maintain a physiological CO of 5.0 ± 0.18 L/min. 
 
4.2 Pressure waveforms and mean arterial pressure 
 
 
Aortic and ventricular pressure waveforms (Figure 27) generated by the flow 
loop, approximated the physiological pressure waveforms. The systolic ventricular and 
aortic pressures peaked over 150 mmHg. The ventricular pressure peaked at 163 ± 3.82 
mmHg and the aortic pressure was 159 ± 2.91/ 56 ± 1.23 mmHg. However, the mean 
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Figure 27: Ventricular and aortic pressure waveform ensemble averaged over 
30 cardiac cycles. 
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arterial pressure (MAP) generated by the loop, which is the average arterial pressure  
over a cardiac cycle [86], was  found to lie within the physiological range of 70 to 110 
mmHg [85]. The MAP was evaluated as: 
𝑀𝐴𝑃 = 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 +  
(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 − 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒)
3
 
 
The MAP generated by the pulsatile flow loop was 90 mmHg. 
 
4.3 Systolic diastolic duration 
 
The systolic duration for the cardiac cycle, can be defined as the interval between 
the onset of the left ventricular pressure rise and closing of the aortic valve (the icisural 
notch observed in the aortic pressure waveform) [87]. Based on this definition, the flow 
loop generated a 0.35 seconds long systole. Thus, the cardiac cycle (0.86 seconds) had a 
systolic duration of 0.35 seconds which implied a diastolic duration of 0.51 seconds.  
This resulted in a systolic diastolic (S/D) ratio of 0.7 which lies within the clinically 
measured range of S/D ratio [88]  
Although the ventricular and aortic pressure waveforms were an approximate of 
the physiological waveforms, the flow loop could still generate a flowrate waveform and 
a cardiac output which was in good agreement with physiological values. The MAP and 
S/D ratio were well within its defined physiological range. These results implicate that 
the flow loop could generate flow within the physiological parameters  
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4.4 Discussion 
The target of this aim was to construct and validate the pulsatile flow loop that 
could replicate physiological flow conditions in the aortic valve and AA. The flow loop 
was tuned by adjusting the compressed air that enabled to generate flow within the 
physiological range of -5 to 20 L/min and a CO of approximately 5 L/min. The aortic 
pressure was adjusted to match the physiological values by altering the resistance and 
compliance, but the aortic pressure peak showed a higher value compared to the 
physiological waveform even after altering the compliance and the resistance of the loop. 
MAP calculated from the aortic pressures values, however lied within the physiological 
range of 70 and 110 mmHg. The S/D ratio also was well within its physiological limits. 
Thus, the flow loop was able to generate a flow rate, MAP and cardiac cycle with S/D 
ratio that lied within the physiological parameters
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CHAPTER 5: 
SPECIFIC AIM 2 
This aim characterized the effect of valvular stenosis on flow dynamics in the 
proximal and the distal ascending aorta (PAA and DAA, respectively). The pulsatile flow 
loop and PIV setup described in sections 3.1 and 0 respectively, were used to capture the 
ensemble-averaged velocity fields in the region of interest. A normal TAV (nTAV) and 
two calcified TAVs (mTAV and sTAV) were used to quantify the impact of the degree of 
stenosis on the instantaneous ensemble-averaged velocity, vorticity, turbulent kinetic 
energy, viscous shear stress (VSS) and Reynolds shear stress (RSS) fields. The flow was 
investigated during the acceleration phase, at peak systole, during the deceleration phase 
and early diastolic phase.  
 
5.1 Velocity Field 
Ensemble-averaged velocity fields at four phases of the cardiac for all three valve 
models are shown in Figure 28. During the acceleration phase, all the valve models 
generated forward flow with distinctive jet structures in the proximal ascending aorta 
(PAA) and the distal ascending aorta (DAA). In the PAA, the nTAV generated a wide 
symmetric low velocity jet, while the reduced valve orifice of the mTAV and sTAV 
caused an increase jet velocity in the PAA. The sTAV resulted in an abnormally high 
velocity jet in the PAA, while relatively low velocities were observed in the distal region 
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for all the valve models during this phase. A high velocity jet in PAA and a low velocity 
jet in the DAA was observed for the sTAV. This variation in the velocity existing 
amongst the two regions (proximal and distal) downstream of the sTAV, can be reasoned 
with the high velocity jet falling out of the plane of observation in the DAA. At peak 
systole, the nTAV generated lowest velocity of all the three valve models. The mTAV 
and sTAV generated a 37% and 117 % increase in velocity, respectively when compared 
to nTAV. A drop in the velocity was observed during the deceleration phase downstream 
of the nTAV, while the mTAV and sTAV continued to demonstrate high velocity jets in 
the DAA and the PAA, respectively. During early diastole, the valve shut close and no 
significant flow structures were observed in any valve model. The fluid velocities 
remained close to zero during this phase.   
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Table 2: Peak velocity data in the AA during the acceleration phase, at peak systole, 
during the deceleration phase and during early diastole 
PAA nTAV mTAV sTAV 
Acceleration 1.2 m/s 1.8 m/s 4.16 m/s 
Peak systole 2.3 m/s 3.3 m/s 5.0 m/s 
Deceleration 1.9 m/s 2.09 m/s 3.19 m/s 
Diastole 0.16 m/s 0.30 m/s 0.33 m/s 
 
DAA nTAV mTAV sTAV 
Acceleration 1.15 m/s 1.69 m/s 0.9 m/s 
Peak systole 1.7 m/s 2.98 m/s 1.04 m/s 
Deceleration 1.39 m/s 2.28 m/s 0.87 m/s 
Diastole 0.06 m/s 0.41 m/s 0.22 m/s 
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Figure 28: Ensemble-averaged velocity fields captured for nTAV, mTAV and sTAV 
valve models (left to right in order) in the PAA (proximal ascending aorta) and the 
DAA (distal ascending aorta) region. 
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5.2  Vorticity Field 
Figure 29 shows the ensemble-averaged out-of-plane vorticity fields at four 
phases of the cardiac cycle for all three valve models. The red and blue colors indicate 
counterclockwise and clockwise vorticity, respectively. The highest magnitude of 
vorticity was found along the edges of the jet emanating from the valves. All three valve 
models produced counterclockwise (positive rotation) vorticity near the convexity of the 
AA, while clockwise (negative rotation) vorticity was observed near the concavity. The 
nTAV model generated the lowest magnitude of vorticity during the acceleration phase, 
when compared to the stenosed valve models. This trend continued at peak systole, as the 
mTAV and sTAV had vorticity magnitude 56% and 200% more than the nTAV. The 
nTAV model exhibited shear layers around the edge of the orifice jet that were both 
symmetrical and parallel to the axis of the valve in the PAA and the DAA. In contrast, 
the mTAV and sTAV generated asymmetric vorticity patterns. The deceleration phase 
was characterized by the same vorticity patterns as those observed at peak systole but 
with reduced magnitude. Vorticity magnitude was relatively low at diastole for all the 
three valve models, when compared with other phases. 
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Table 3: Ensemble-averaged vorticity data captured during the acceleration phase, at peak 
systole, during the deceleration phase and during early diastole 
PAA nTAV mTAV sTAV 
Acceleration 498 s-1 870 s-1 2795 s-1 
Peak systole 1165 s-1 1816 s-1 3493 s-1 
Deceleration 578 s-1 944 s-1 2479 s-1 
Diastole 115.8 s-1 253.4 s-1 435 s-1 
 
DAA nTAV mTAV sTAV 
Acceleration 519 s-1 702 s-1 724 s-1 
Peak systole 732 s-1 1176 s-1 826 s-1 
Deceleration 542 s-1 656 s-1 673 s-1 
Diastole 107 s-1 284 s-1 270 s-1 
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Figure 29: Ensemble-averaged vorticity fields captured for nTAV, mTAV and sTAV 
valve models (left to right in order) in the PAA (proximal ascending aorta) and the 
DAA (distal ascending aorta) region. 
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5.3  Viscous and Reynolds Shear Stress Fields  
The distributions of viscous shear stress (VSS) at four phases of the cardiac cycle 
for all three valve models is shown in Figure 30. The VSS plots exhibit some similarities 
with the vorticity plots, as the regions of maximum shear stress are found along the edges 
of the jet. This phenomenon is expected as the highest velocity gradients are found near 
the regions of flow separation. Low VSS magnitude was associated with nTAV 
throughout the cardiac cycle. However, a noticeable difference between the VSS fields 
was observed amongst the stenosed valves during the acceleration phase. Elevated VSS 
dominated the DAA and PAA downstream of the mTAV and sTAV, respectively. A 
similar trend was observed at peak systole, but with higher VSS magnitude. The reduced 
valve orifice produced by the mTAV and sTAV led to the narrowing of the jet, causing a 
150% increase in VSS for mTAV and 216% increase for sTAV, relative to the nTAV. 
During the deceleration phase, regions of high VSS continued to occupy the mTAV DAA 
and sTAV PAA. VSS values were low for all valve models during diastole.  
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Table 4: Ensemble-averaged VSS data captured during the acceleration phase, at peak 
systole, during the deceleration phase and during early diastole. 
PAA nTAV mTAV sTAV 
Acceleration 0.21 N/m2 0.44 N/m2 2.8 N/m2 
Peak systole 1.04 N/m2 2.6 N/m2 3.2 N/m2 
Deceleration 0.41 N/m2  0.43 N/m2 2.0 N/m2 
Diastole 0.01 N/m2 0.03 N/m2 0.08 N/m2 
 
DAA nTAV mTAV sTAV 
Acceleration 0.23 N/m2 0.31 N/m2 0.66 N/m2 
Peak systole 0.54 N/m2 1.12 N/m2 1.02 N/m2 
Deceleration 0.19 N/m2  0.39 N/m2 0.56 N/m2 
Diastole 0.02 N/m2 0.017 N/m2 0.11 N/m2 
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Figure 30: Ensemble-averaged VSS fields captured for nTAV, mTAV and sTAV valve 
models (left to right in order) in the PAA (proximal ascending aorta) and the DAA (distal 
ascending aorta) region. 
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Figure 31 shows the Reynolds shear stress (RSS) fields for all three valve models 
at four phases of the cardiac cycle. Irrespective of the degree of stenosis, the two stenosed 
valve models generated peak RSS values two-orders of magnitude greater than the peak 
VSS, thus it can be deduced that the flow was dominated by turbulent stresses. These 
turbulent effects were more prominent in the wake of the valve leaflets where the 
turbulence and velocity fluctuations attained their maximum. During the acceleration 
phase, significant differences were observed, nTAV had relatively low RSS magnitude 
throughout the AA, whereas the convexity of mTAV DAA and sTAV PAA featured 92% 
and 267% increase in RSS magnitude, respectively when compared with the nTAV. At 
peak systole, nTAV had a maximum RSS value of 165 N/m2 while mTAV and sTAV 
showed a 39 % and 200 % increase, respectively. During the deceleration phase, high 
RSS regions were still prevalent in the mTAV DAA, while very low velocity fluctuations 
were measured throughout the nTAV AA. The diastolic phase did not exhibit any 
substantial difference in RSS between the valve models and was characterized with very 
low RSS magnitude for all the valve models, when compared to other phases. 
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Table 5: RSS data captured during the acceleration phase, at peak systole, during the 
deceleration phase and during early diastole 
 
PAA nTAV mTAV sTAV 
Acceleration 85 N/m2 163 N/m2 307 N/m2 
Peak systole 165 N/m2 230 N/m2 502 N/m2 
Deceleration 108 N/m2 120 N/m2 250 N/m2 
Diastole 3.24 N/m2 3.0 N/m2 5.4 N/m2 
 
DAA nTAV mTAV sTAV 
Acceleration 86 N/m2 225 N/m2 70 N/m2 
Peak systole 98 N/m2 203 N/m2 105 N/m2 
Deceleration 71.6 N/m2 170 N/m2 82 N/m2 
Diastole 2.15 N/m2 5.2 N/m2 4.3 N/m2 
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Figure 31: Ensemble-averaged RSS fields captured for nTAV, mTAV and sTAV 
valve models (left to right in order) in the PAA (proximal ascending aorta) and the 
DAA (distal ascending aorta) region. 
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5.4  Turbulent Kinetic Energy 
Turbulent Kinetic Energy (TKE) fields at four phases of the cardiac cycle for all 
three valve models are shown in Figure 32. Following the trend observed with the RSS 
distribution, the nTAV resulted in the lowest TKE. A sharp increase in TKE was 
observed near the convexity of the mTAV DAA during the acceleration phase. The sTAV 
model showed similar characteristics in the PAA. While valvular stenosis generated up to 
300% increase in TKE relative to the nTAV, at peak systole; the affected region 
depended upon the degree of stenosis. The mTAV caused 113 % increase in DAA 
relative to nTAV. sTAV generated high TKE values close to the valve leaflets in the 
PAA, a 286 % increase, when compared to nTAV.  During the deceleration phase, the 
stenosed valves continued to generate high TKE, while low TKE was observed for all the 
valve models during diastole. 
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Table 6: TKE data captured during the acceleration phase, at peak systole, during the 
deceleration phase and during diastole. 
 
PAA nTAV mTAV sTAV 
Acceleration 0.59 m2/s2 0.96 m2/s2 1.02 m2/s2 
Peak systole 1.45 m2/s2 1.2. m2/s2 5.6 m2/s2 
Deceleration 0.51 m2/s2 0.5 m2/s2 1.44 m2/s2 
Diastole 0.02 m2/s2 0.02 m2/s2 0.05 m2/s2 
 
DAA nTAV mTAV sTAV 
Acceleration 0.33 m2/s2 1.31 m2/s2 0.37 m2/s2 
Peak systole 0.43 m2/s2 3.2. m2/s2 0.84 m2/s2 
Deceleration 0.31 m2/s2 0.97 m2/s2 0.34 m2/s2 
Diastole 0.017 m2/s2 0.18 m2/s2 0.13 m2/s2 
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Figure 32: Ensemble-averaged TKE fields captured for nTAV, mTAV and sTAV valve 
models (left to right in order) in the PAA (proximal ascending aorta) and the DAA (distal 
ascending aorta) region. 
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5.5 Effective orifice area  
 The effective orifice area for all three valve models were calculated using the 
Gorlin equation mentioned in 1.4.2.1 Diagnosis. The calculated EOA for all the three 
valve models were 2.21 cm2 for the nTAV model (normal TAV), 1.18 cm2 for the mTAV 
model (moderately stenosed valve model) and 0.69 cm2 for sTAV (severely stenosed 
valve model).  
 The effective orifice area calculated from the PIV images for the nTAV model 
was 2.01 cm2, for the mTAV model was 1.28 cm2 and for the sTAV was 0.72 cm2. The 
area was calculated at the location of vena-contracta for all the three valve models. The 
effective orifice area was evaluated from the velocity jets observed in the velocity field 
obtained from PIV. 
 The values of effective orifice are calculated for all the three valve models were 
within the range defined for calcific aortic stenosis by AHA statistics. 
5.6  Discussion 
The goal of this aim was to study the effect of valvular stenosis on aorta 
hemodynamics by implementing PIV to characterize the flow downstream of the normal 
aortic valve model nTAV, and its stenosed counterparts, mTAV and sTAV. In this aim, 
the hemodynamics in the proximal and the distal region of the AA, across the three valve 
models were compared using ensemble averaged velocity, vorticity, viscous shear stress, 
nTAV mTAV sTAV 
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Reynolds shear stress and turbulent kinetic energy fields at acceleration, peak systole, 
deceleration and early diastolic phases of the cardiac cycle.  
This study used a common aorta phantom for all the three valve models which 
allowed to evaluate and seclude the impact of aortic valve stenosis on aorta 
hemodynamics. The reduced valve orifice for the stenosed valve models generated 
hemodynamic alterations which were characterized by elevated jet velocities. The sTAV 
with the highest degree of stenosis was associated with the maximum jet velocity out of 
the two stenosed valve models. This observation implies that the magnitude of jet 
velocity was highly dependent on the severity of stenosis. These findings were in line 
with the previous invitro, and computational studies that studied the impact of stenosis 
over valvular flow [63], [64], [89]. The nTAV model showed a jet like flow in the 
ascending aorta. However, the flow was more of three dimensional in case of stenosed 
valve models. This is observed in case of sTAV model where the three-dimensional 
characteristic of the jet caused it to fall out of the plane of the measurement. The 
dependence of hemodynamic alterations over the degree of stenosis was observed for all 
the flow metrics. Vorticity and VSS magnitudes were relatively higher downstream of the 
stenosed valve models, when compared to the healthy one. Regions of elevated VSS were 
present in both the convexity and concavity of the AA. This suggested that the regions of 
elevated VSS corresponded to the symmetric dilation pattern associated with TAV AA. 
High VSS was prevalent in the stenosed valve flow filed not only for the peak systole but 
also during the acceleration and the deceleration phase of the cardiac cycle. This 
highlight the fact that the aortic wall was exposed to higher VSS for a longer duration in 
case of stenosed valve models, when compared to normal valve.in a cardiac cycle.  The 
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degree dependent characteristic of VSS were also found to match the findings of the 
previous MRI and invitro studies [64], [90], [91]   
The intensity of fluctuations in the flow filed was characterized in terms of TKE 
and RSS which are both evaluated using fluctuating components of velocities. Both TKE 
and RSS were dependent on the severity of stenosis, with the maximum values associated 
with the severely stenosed valve. 
The effective orifice area calculated using Gorlin equation for this study 
approximated the effective orifice area measured from the flow images, captured using 
particle image velocimetry. This implies that stenosed valve models designed using 
commissural fusion could generate stenosis with effective orifice area equal to the values 
calculated mathematically. These calculated and measured effective orifice areas for all 
the three valve models were within the clinically defined physiological ranges. 
Overall these results have demonstrated that valvular stenosis significantly altered 
the flow downstream of the stenosed valves in the AA when compared to normal aortic 
valve. The results also show that these flow abnormalities were concentrated in the 
regions prone to dilation in CAS aortopathy. In vivo studies have associated elevated wall 
shear stress in the AA with aortic stenosis using magnetic resonance imaging and thus 
support the finding of this study [90], [91]. Shear stresses alterations in the AA can result 
in abnormal biological responses from aorta wall endothelium leading to progressive 
tissue alterations, aorta wall remodeling with possible dilation and dissection. In vivo 
studies subjecting endothelial cells to chronic shear stress support this claim [92].  These 
observations provide increasing evidence for the involvement of hemodynamics in the 
stenosis associated aortopathy. These results isolate the impact of CAS on aorta flow in a 
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non-dilated compliant silicon aorta model. The results demonstrate the impact of CAS on 
AA hemodynamics in regions prone to dilations providing more evidence to the existence 
of hemodynamic pathway in CAS aortopathy. These hemodynamic alterations could 
cause adverse biological response from the aortic wall leading a positive feedback cycle 
and accelerating disease progression. These observations suggest that there is a need to 
further investigate the effects of flow abnormalities on aorta wall biology. Thus 
histopathological studies should be performed in future to assess the impact of these 
hemodynamic alterations on aortic tissue. 
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CHAPTER 6: 
SPECIFIC AIM 3 
This aim evaluated the effect of valvular stenosis on left ventricular (LV) 
function. Due to impaired leaflet motion and narrowed valvular orifice, the blood flow is 
restricted. To maintain the same CO, the left ventricle must perform additional work. 
This overload imposed by a stenosed valve on the left ventricle is evaluated in this aim.  
6.1  Ventricular work 
The pressure-volume (PV) graphs (Figure 33) were plotted and the left ventricular 
work for each valve model was calculated by evaluating the area under its associated PV 
curves.  
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Figure 33: Figure shows the pressure-volume graphs for all three valve 
models: nTAV, mTAV and sTAV. 
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An increase in the ventricular pressure was observed for each of the stenosed 
valve models. The peak systolic pressure for mTAV was approximately 175 mmHg while 
that for sTAV was around 200 mmHg. 
 
As shown in the Figure 34, the nTAV was associated the lowest amount of ventricular 
work. The introduction of valvular stenosis caused ventricular overload of 16% for the 
mTAV and 27 % for the sTAV, when compared with the normal valve. 
 
6.2 Discussion 
This aim evaluated the amount of work, the LV does to maintain the physiological 
cardiac output in case of valvular stenosis. In CAS, the aortic valve undergoes structural 
changes in the form of leaflet stiffening, reduced valve orifice and impaired leaflet 
motion generating obstruction to the blood flowing in to the aorta. To overcome this 
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Figure 34: Bar graph showing left ventricular work associated with each 
of the valve models: nTAV, mTAV and sTAV 
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obstruction and maintain the CO, the ventricle is subjected to an overload. In this study 
valvular stenosis, imposed up to 27 % of overload on the left ventricular. The amount of 
ventricular overload increased with the severity of stenosis. Clinical studies have shown 
ventricular overload to increase LV mass and wall thickness, causing LV hypertrophy 
and heart failure [93]. Thus, the results of this aim demonstrate the association of aortic 
stenosis with LV overload, and its impact on LV function in a degree dependent manner.
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CHAPTER 7: 
CONCLUSION 
CAS is a slow progressive disease characterized by reduced valve orifice and 
impaired leaflet motion of the aortic valve and has been associated with aortopathy and 
left ventricular dysfunction. This in vitro study isolated the impact of the degree of 
valvular stenosis on left ventricular workload and aorta hemodynamics. The results of 
this study demonstrated 1) altered hemodynamics in the aorta in case of stenosed valves, 
2) excess ventricular workload imposed due valvular stenosis. Stenosis resulted in 
regions of elevated velocity, shear stress and turbulence at locations prone to dilation in 
the aorta, providing additional evidence to the hemodynamic theory of CAS associated 
aortopathy. The excess ventricular work in case of the stenosed valves explain the 
association of ventricular hypertrophy with aortic stenosis. The findings of this study thus 
explain the susceptibility of CAS patients to aortopathy and heart failure. 
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CHAPTER 8: 
LIMITATIONS 
This study had considerable limitations that requires attention. The PIV setup 
allowed to capture the flow in 2-dimensions, while a 3-dimensional flow field would 
have provided better understanding of the flow structures downstream of the aortic valve. 
This limitation might explain the drastic change in the velocity amongst the proximal and 
distal sections of sTAV aorta, since the high velocity jet was oriented outside the span of 
the 2-dimensional measurement plane in the distal region. However, this did not halter 
the study from demonstrating significant flow differences that existed downstream of the 
three valve models. The near wall flow characteristics could not be characterized using 
PIV due to non-homogenous seeding near the wall as the particles tend to move away 
from the wall. The aortic and ventricular pressures generated by the flow loop 
approximated the physiological values. This can be linked to the insufficiency of the flow 
loop to mimic the systemic compliance and resistance. The cardiac output and the 
instantaneous flow rate generated by the flow loop, however were well within the 
physiological limits. Porcine aortic valve models were used in this study and valvular 
stenosis was modelled using commissural fusion. The reliability of this method to mimic 
stenosis was questionable because the artificial reduction created in the valve orifice to 
model stenosis was heavily idealized based on trial and error. However, the downstream 
flow velocity in the aorta and the transvalvular pressure gradient obtained from the PIV 
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post processing and pressure transducers respectively, lied well within the AHA statistics 
for aortic stenosis.  
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